Ossium Health is a bioengineering company that has created an industrial-scale, on-demand bank of bone marrow recovered from organ donors and is developing stem-cell therapies for life-threatening blood and immune diseases. Its proprietary recovery, processing, and cryopreservation methods produce marrow the company says is phenotypically and functionally equivalent to cells from living donors and can be delivered months faster than traditional volunteer-donor options. Ossium partners with Organ Procurement Organizations representing just over half of U.S. organ donors to recover vertebral bodies, process marrow, and store product indefinitely until requested by treating physicians. Near-term clinical focus is on hematologic malignancy treatments, while additional programs target reducing rejection in organ transplants; the company is collaborating with Columbia University Medical Center on a Phase I intestinal transplant study. The company will also launch Ossigraft, an orthopedic product derived from the same vertebral bodies, which is slated to enter the clinic in the second half of 2023. Founded in 2016 and led by CEO Kevin Caldwell, Ossium is an FDA-registered tissue bank, accredited by COLA, and operates a CLIA-certified laboratory. Ossium Health develops cell therapies using a unique deceased-donor bone marrow banking platform. Its lead program, OSSM-007, is an interferon-gamma‑primed mesenchymal stem cell product being developed to treat steroid-refractory acute graft versus host disease (GVHD). The company says the CIRM award will accelerate pre-clinical and manufacturing activities and support initiation of clinical study activities by the end of 2023. Ossium’s pipeline targets hematologic diseases, organ rejection, and orthopedic trauma. The company was founded in 2016 and is led by co‑founders Kevin Caldwell (President & CEO) and Erik Woods (EVP & Chief Science Officer). Ossium Health is a therapeutics company that leverages a deceased donor bone marrow banking platform to develop stem cell therapies for patients with life‑threatening blood and immune diseases. Founded in 2016 and based in San Francisco, the company is led by Co‑Founder, President & CEO Kevin Caldwell and Co‑Founder, EVP & Chief Science Officer Erik Woods. Ossium uses donor‑matched hematopoietic stem cells and mesenchymal stem cells as the basis for its therapeutic programs. The company plans an initial suite of clinical trials to use donor‑matched hematopoietic stem cells to re‑educate organ recipients’ immune systems to accept donor organs. It also intends to deploy the anti‑inflammatory properties of mesenchymal stem cells to promote healing in patients with fistulizing Crohn’s disease. Another planned program aims to reset the malignant immune systems of hard‑to‑match blood cancer patients via bone marrow transplants from organ donors.

Total raised

$118M

Funding rounds

3

Latest round

Series C

Latest activity

Jul 2023